Pharma
Consumers are increasingly self-empowered in their care decisions -- and place a growing premium on…
A robust web presence and offerings like online scheduling and telehealth are imperatives for health systems looking to stay relevant.
A new exploratory collaboration with Ironwood Pharmaceuticals comes just a couple weeks after the digital therapeutics startup ended a commercialization relationship with Novartis' Sandoz.
This week at the Connected Health Conference in Boston, Bob Coughlin, executive director of the Mass Biotech Council, and Dr. Joe Kvedar, VP of Connected Health at Partners, talked the future of digital in life sciences.
Closed Loop Medicine CEO and co-founder Hakim Yadi discusses why the development of digital health technologies should not stray "too far away" from the academic and clinic rigor applied to the pharma industry.
Once Fitbit has cleared its own atrial fibrillation detection feature, it will be working with the pharmas to develop content that will help at-risk users discuss their heart health with a provider.
The pharma's Sandoz division will be handing commercialization of reSET, reSET-O and future therapies back to Pear over the course of a transition period.
The company will focus on digitally connecting its offerings, which are currently in use by more than 5,000 clinical trial sites and sponsors.
Because digital health is inherently different from other kinds of innovation like drug trials, the rules need to be rewritten, says Sunita Patolia, team lead for human-centered design at Partners HealthCare Pivot Labs.
Also: OptimizeRx delivers messaging through NewCrop's electronic prescription software; Novo Nordisk expands collaboration with Noom following strong pilot; Livongo signs its biggest payer yet.
Novartis has also announced that it will be opening a new AI innovation lab.